# Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Hypertension After Transcatheter Mitral Valve Edge-to-Edge Repair (M-TEER): A Prospective Cohort Study

> **NCT07662655** · EARLY_PHASE1 · RECRUITING · sponsor: **Xiamen Cardiovascular Hospital, Xiamen University** · enrollment: 60 (estimated)

## Conditions studied

- Pulmonary Hypertension
- Pulmonary Hypertension Associated With HFpEF

## Interventions

- **DEVICE:** Percutaneous Pulmonary Artery Denervation (PADN)
- **DRUG:** Control group (receiving standard medical therapy alone)

## Key facts

- **NCT ID:** NCT07662655
- **Lead sponsor:** Xiamen Cardiovascular Hospital, Xiamen University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-06
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07662655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07662655, "Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Hypertension After Transcatheter Mitral Valve Edge-to-Edge Repair (M-TEER): A Prospective Cohort Study". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07662655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*